scispace - formally typeset
Search or ask a question
Institution

Jewish Hospital

HealthcareCincinnati, Ohio, United States
About: Jewish Hospital is a healthcare organization based out in Cincinnati, Ohio, United States. It is known for research contribution in the topics: Antigen & Population. The organization has 3881 authors who have published 3414 publications receiving 123044 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: Although the PEG resorbable liquid membrane is easy to use and forms an occlusive layer, caution is recommended when using the membrane over an unsupported defect; the membrane did not maintain the desired bone regeneration volume with the unfilled and autogenous bone grafted groups.
Abstract: Objectives. The aims of this study were to test whether or not the application of an in situ–formed synthetic polyethylene glycol hydrogel (PEG) used as a biodegradable membrane for guided bone regeneration with a variety of graft materials and ambient oxygen or hyperbaric oxygen (HBO) environments would result in enhanced bone regeneration, and to observe the histologic and histomorphometric aspects of bone healing of the calvarial defects with and without a PEG membrane. Study design. Thirty adult, skeletally mature, male New Zealand white rabbits were randomly divided into 3 groups of 10 animals each. Bilateral 15-mm-diameter critical-size defects were created in the parietal bones of each animal. Group 1 served as a control with unfilled bilateral calvarial defects, group 2 had bilateral calvarial defects filled with morcelized autogenous calvarial bone, and group 3 had bilateral calvarial defects filled with a biphasic calcium phosphate ceramic. One of the calvarial defects was randomly protected with a PEG resorbable liquid membrane in each animal. Five animals from each group underwent a course of HBO treatment (2.4 ATA 100% oxygen for 90 minutes 5 days a week for 4 weeks) and the other 5 served as control and did not receive any supplemental oxygen (normobaric). The animals were killed 6 weeks after their surgery, and their parietal bones were harvested. The specimens were analyzed with microscopic computerized tomography (microCT) scans and histomorphometrics. Results. The unfilled normobaric control bony defects did not heal, proving the critical-size nature of these defects. The presence of autogenous bone or bone ceramic in the defects increased the bone volume fraction and bone mineral density of the defects (P .001). The presence of a membrane in the ungrafted and autogenous bone grafted defects resulted in a decrease in the corrected bone volume fraction (P .002) but not in the bone ceramic grafted defects (P .580). Bony healing of defects where the membrane was unsupported was compromised; the membrane did not maintain the desired bone regeneration volume with the unfilled and autogenous bone grafted groups. The PEG resorbable liquid membrane worked best with the bone ceramic material. HBO did not ameliorate the healing of the autogenous bone graft or ceramic filled defects in the 6week time period of this study. Conclusions. Although the PEG resorbable liquid membrane is easy to use and forms an occlusive layer, caution is recommended when using the membrane over an unsupported defect. HBO did not ameliorate bony healing with the membrane at the early 6-week time point. The authors recommend future assessment with HBO at the 12-week time

51 citations

Journal ArticleDOI
TL;DR: Characteristic features of the entire group, exclusive of Type IId included a posteriorly oriented loop directed toward the “Z” axis and relatively narrow loops especially in the frontal and right sagittal plane, which appear characteristic for the group of patients with PMD.

50 citations

Journal ArticleDOI
T Gulick1, S J Pieper1, M A Murphy1, L G Lange1, G F Schreiner1 
TL;DR: A new method of in vitro cardiac contractility assessment that has significant advantages over existing systems has been developed and characterized and enabled description of an inhibitor of cardiac contractile function produced by activated immune cells.
Abstract: BACKGROUND Potentially reversible congestive heart failure accompanies disease states associated with an immune cell myocardial infiltrate such as cardiac allograft rejection and inflammatory myocarditis. We therefore examined the hypothesis that immune cells can produce noncytotoxic alterations in cardiac function. METHODS AND RESULTS A novel system to evaluate cultured cardiac myocyte contractility was developed using neonatal rat cardiocytes grown on human amniotic membrane segments. Spontaneous synchronous cell beating produced macroscopic distortion of these membranes. Movement of free-floating membranes anchored within a perfusion chamber was visualized under low-power microscopy and measured from recordings of the rhythmic displacement of membrane-adherent markers. Additions of graded concentrations of isoproterenol to the perfusate produced up to threefold increases in the initial contractile phase velocity (contractile index), with an EC50 of 10(-7) M. When the extracellular Ca2+ concentration was increased from 0.9 to 3.6 mM, 2.43-fold increases in this index occurred. Myocytes incubated for 72 hours in the presence of dilutions of medium conditioned by activated rat splenic macrophages and lymphocytes exhibited an isoproterenol contractile index inhibited by 62% compared with control cells. In contrast, responses of supernatant-exposed and control cells to increased extracellular Ca2+ concentrations were not significantly different. Parallel studies of increases in myocyte intracellular adenosine 3':5'-cyclic monophosphate concentrations in response to isoproterenol stimulation demonstrated correlative inhibition that was specific for exposure to medium conditioned by immune cells. CONCLUSION Thus, a new method of in vitro cardiac contractility assessment that has significant advantages over existing systems has been developed and characterized. This new method has enabled description of an inhibitor of cardiac contractile function produced by activated immune cells.

50 citations

Journal ArticleDOI
TL;DR: It is demonstrated that arsenic trioxide, in a dose that could produce clinically comparable serum concentrations to those observed in humans, causes cardiotoxicity.
Abstract: Arsenic trioxide is highly effective in the treatment of acute promyelocytic leukemia (APL) In September 2000, the Trisenox brand of arsenic trioxide for the treatment of relapsed and refractory APL was approved in the United States A recent clinical report has shown a serious ventricular tachycardia at the therapeutic doses of arsenic trioxide in APL patients The present study was undertaken to investigate the cardiotoxic effect of arsenic trioxide using a mouse model Animals were injected intraperitoneally with arsenic trioxide 5 mg/ kg/d for 30 d, a dose regiment that has been shown to produce plasma concentrations of arsenic within the range of those present in arsenic-treated APL patients Analysis of myocardial function revealed that arsenic caused a significant decrease in the maximum rate of rise in intraventricular pressure during ventricular contraction (MAX dP/dt), and significant increases in the end diastolic pressure and ventricle minimum diastolic pressure In response to B-adrenergic stimulation by isoproterenol, the arsenic-treated heart did not show increase in MAX dP/dt, which was observed as a stress response in the saline-treated controls The functional alterations were accompanied by cardiomyopathy, as revealed by histopathological and ultrastructural examination Furthermore, arsenic caused myocardial apoptosis, as determined by a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay, which was confirmed by caspase-3 activation detected by enzymatic assay Our study thus demonstrates that arsenic trioxide, in a dose that could produce clinically comparable serum concentrations to those observed in humans, causes cardiotoxicity

50 citations

Journal ArticleDOI
01 Feb 1983-Chest
TL;DR: Clinical improvement was observed along with normalization of the pressure-volume curve and a decline in the upstream resistance in patient 3 (bronchiolitis obliterans with interstitial pneumonitis).

50 citations


Authors

Showing all 3894 results

NameH-indexPapersCitations
John C. Morris1831441168413
David L. Kaplan1771944146082
Robert H. Purcell13966670366
Nancy J. Cox135778109195
Jennifer S. Haas12884071315
David A. Cheresh12533762252
John W. Kappler12246457541
Philippa Marrack12041654345
Arthur Weiss11738045703
Thomas J. Kipps11474863240
Michael Pollak11466357793
Peter M. Henson11236954246
Roberto Bolli11152844010
William D. Foulkes10868245013
David A. Lynch10871459678
Network Information
Related Institutions (5)
United States Department of Veterans Affairs
70.9K papers, 3.2M citations

93% related

Baylor College of Medicine
94.8K papers, 5M citations

93% related

University of Texas Southwestern Medical Center
75.2K papers, 4.4M citations

93% related

University of California, San Francisco
186.2K papers, 12M citations

92% related

Brigham and Women's Hospital
110.5K papers, 6.8M citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20232
202217
202148
202038
201944
201828